These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 8598609)

  • 21. [Economic evaluation and prediction of hepatitis B immunization strategy in Shenzhen, China].
    Sun PP; Zhang SX; Xia Y
    Zhonghua Yu Fang Yi Xue Za Zhi; 2018 Jul; 52(7):743-747. PubMed ID: 29996303
    [No Abstract]   [Full Text] [Related]  

  • 22. [Analysis on economic efficacy regarding previous strategies and current recommendations for vaccination against hepatitis B virus in China].
    Zhang SX; Dang RB; Zhang WD; Liang XF; Cui FQ
    Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Oct; 29(10):1003-8. PubMed ID: 19173882
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Cost-benefit analysis on immunization of newborns with hepatitis B vaccine in Jinan City].
    Liu ZG; Zhao SL; Zhang YX
    Zhonghua Liu Xing Bing Xue Za Zhi; 1995 Apr; 16(2):81-4. PubMed ID: 7781052
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost effectiveness of hepatitis B vaccination strategies in Ireland: an economic evaluation.
    Tilson L; Thornton L; O'Flanagan D; Johnson H; Barry M
    Eur J Public Health; 2008 Jun; 18(3):275-82. PubMed ID: 18160389
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Should Canada and the United States universally vaccinate infants against hepatitis B? A cost-effectiveness analysis.
    Krahn M; Detsky AS
    Med Decis Making; 1993; 13(1):4-20. PubMed ID: 8433635
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-benefit analysis of a nationwide inoculation programme against viral hepatitis B in an area of intermediate endemicity.
    Ginsberg GM; Berger S; Shouval D
    Bull World Health Organ; 1992; 70(6):757-67. PubMed ID: 1486673
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Confusing games of public insurance with hepatitis B vaccinations. Interview by Dr. rer. nat. Anita Schweiger].
    Eichhorn R
    Fortschr Med; 1997 Apr; 115(10):41. PubMed ID: 9206686
    [No Abstract]   [Full Text] [Related]  

  • 28. Desirability and feasibility of hepatitis B vaccine in EPI.
    Mittal SK
    Indian J Pediatr; 2001 Mar; 68 Suppl 1():S61-5. PubMed ID: 11411388
    [No Abstract]   [Full Text] [Related]  

  • 29. [Evaluation of economic outcomes of "hepatitis B vaccine event reported by media" in China, 2013].
    Zhang SX; Sun PP; Xia Y
    Zhonghua Yu Fang Yi Xue Za Zhi; 2018 Aug; 52(8):837-841. PubMed ID: 30107719
    [No Abstract]   [Full Text] [Related]  

  • 30. Cost-benefits of vaccination programmes.
    Szucs T
    Vaccine; 2000 Feb; 18 Suppl 1():S49-51. PubMed ID: 10683547
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 2-dose hepatitis vaccination versus 3-dose regimen.
    Cruess DF
    Pediatrics; 2002 Jun; 109(6):1183; author reply 1183-4. PubMed ID: 12042565
    [No Abstract]   [Full Text] [Related]  

  • 32. Universal hepatitis B vaccination: the economics of prevention.
    Krahn MD; Detsky AS
    CMAJ; 1992 Jan; 146(1):19-21. PubMed ID: 1530815
    [No Abstract]   [Full Text] [Related]  

  • 33. Economic analysis of promotion of hepatitis B vaccinations among Vietnamese-American children and adolescents in Houston and Dallas.
    Zhou F; Euler GL; McPhee SJ; Nguyen T; Lam T; Wong C; Mock J
    Pediatrics; 2003 Jun; 111(6 Pt 1):1289-96. PubMed ID: 12777543
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Economic evaluation on infant hepatitis B vaccination combined with immunoglobulin in China, 2013.
    Chen YS; Zheng H; Liu YM; Wang FZ; Wu ZH; Miao N; Sun XJ; Zhang GM; Cui FQ; Liang XF
    Hum Vaccin Immunother; 2016 Jul; 12(7):1838-46. PubMed ID: 26891075
    [No Abstract]   [Full Text] [Related]  

  • 35. [Study on the cost-effectiveness, benefit and utility analysis on the infant inoculation hepatitis B vaccine in Shanghai].
    Wu GY; Gong YL; Yu SL; Shao RT; Qin HJ
    Zhonghua Liu Xing Bing Xue Za Zhi; 2004 Jun; 25(6):474-8. PubMed ID: 15231120
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-benefit analysis of the introduction of mass vaccination against hepatitis B in Italy.
    Demicheli V; Jefferson TO
    J Public Health Med; 1992 Dec; 14(4):367-75. PubMed ID: 1489561
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of hepatitis A/B vaccination in the private sector.
    Jacobs RJ; Meyerhoff AS
    Sex Transm Dis; 2005 Aug; 32(8):465. PubMed ID: 16041246
    [No Abstract]   [Full Text] [Related]  

  • 38. [Studies on immunization strategies for hepatitis B in different endemic areas of China].
    Wang L; Li H; Wang S; Gong J; Zeng X; Li R; Nong Y; Huang Y; Chen X; Huang Z
    Zhonghua Yu Fang Yi Xue Za Zhi; 1999 Mar; 33(2):104-6. PubMed ID: 11864465
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevaccination screening for hepatitis B among sexually active adolescents and young adults.
    Buffington J; Mast EE
    Clin Infect Dis; 1998 Dec; 27(6):1562-3. PubMed ID: 9868699
    [No Abstract]   [Full Text] [Related]  

  • 40. Cost-effectiveness analysis of a hepatitis B vaccination catch-up program among children in Shandong Province, China.
    Jia Y; Li L; Cui F; Zhang D; Zhang G; Wang F; Gong X; Zheng H; Wu Z; Miao N; Sun X; Zhang L; Lv J; Yang F
    Hum Vaccin Immunother; 2014; 10(10):2983-91. PubMed ID: 25483678
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.